Fig. 5

Pharmacologic modulation of the central dopaminergic system influences dystonia-like phenotype in Tor1a+/- but not wt mice. a Diagram demonstrates abnormal movements measured by the DLMS of Tor1a + -/ mice before and after sciatic nerve crush during an observation time of 8 weeks. 3 groups of mice are investigated: Naïve mutant mice (dark grey line; n = 33), Tor1a+/- mice treated with AMPT (light grey line; n = 13) and L-Dopa/benserazide (black line; n = 14) (mean ± SEM). b Focal DLM score of 3 groups of wt mice before and after sciatic nerve crush is shown (naïve mice - dark grey line, n = 30; AMPT treated mice – light grey line, n = 9; L-Dopa/benserazide treated mice – black line, n = 10) (mean ± SEM). § demonstrates a significant difference after Bonferroni-Holm correction of the p-values (non-parametric two-tailed Mann-Whitney test) for the whole time span of 8 weeks comparing either (a) naïve nerve injured Tor1a+/- or (b) wt mice with AMPT or L-Dopa/benserazide treated mice of the same genotype for all time points. c, d Diagrams show (c) relative DA and (d) HVA level contralateral to the crush injury side of naïve (n = 6) and Tor1a+/- mice 1 day after nerve crush (n = 5) as well as crush injured mutant mice that received either AMPT (4 h after injection of the last of 3 AMPT administrations, n = 5) or L-Dopa/benserazide treatment (90 min after injection of L-Dopa, n = 5) (mean ± SD). e, f Diagrams demonstrate (e) relative DA and (f) HVA level contralateral to the crush injury in wt mice that were treated with either AMPT (n = 5) or L-Dopa/benserazide treatment (n = 5) (mean ± SD). Statistical analysis was performed by using the parametric one-way ANOVA with posthoc Tukey test. *p < 0.05, **p < 0.01